Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw

Nature Clinical Practice Rheumatology

Volumn 5, Issue 1, 2009, Pages 6-7

  Sambrook, Philip N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

ANALGESIA; ARTICLE; BONE CANCER; BONE NECROSIS; BONE PAIN; CANADA; CANCER PATIENT; CLINICAL TRIAL; CONSENSUS; DEBRIDEMENT; DENTAL CARE; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; JAW DISEASE; LOW DRUG DOSE; MEDICAL SOCIETY; MOUTH EXAMINATION; MOUTH HYGIENE; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETREATMENT; RISK ASSESSMENT; RISK FACTOR; SECONDARY INFECTION; SURGICAL WOUND; TREATMENT DURATION; WOUND HEALING;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CANADA; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JAW DISEASES; OSTEITIS DEFORMANS; OSTEONECROSIS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 58049220186     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0960     Document Type: Article

References (10)

1. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61: 1115-1117
2. Carter GD and Goss AN (2003) Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48: 268
3. Ruggiero SL et al. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62: 527-534
4. Caro JJ et al. (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 1003-1008
5. Khosla S et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491
6. Hoff AO et al. (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 24 (Suppl): A8528
7. Mavrokokki T et a. (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415-423
8. Khan AA et al. (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35: 1-7
9. Yarom N et al. (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis Int 18: 1363-1370
10. Black DM et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296: 2927-2938